PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Alto Marketing Ltd

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

TTP LabTech Announces 25% Revenue Growth and A Push on R&D - TTP LabTech has announced a significant 25% increase in total revenue for the last fiscal year
TTP LabTech Announces 25% Revenue Growth and A Push on R&D

 

NewswireToday - /newswire/ - Royston, United Kingdom, 2009/04/28 - TTP LabTech has announced a significant 25% increase in total revenue for the last fiscal year.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

TTP LabTech has today announced a 25% increase in total revenue for the last fiscal year. Bucking the trend, TTP LabTech’s products have sustained continued growth within the last 12 months, generating revenues of £9.1 million compared with £7.3 million from the previous year. Furthermore, this is the first year that the revenue generated by the product business has overtaken that of their custom development business. As a result, there will be a 20% increase in R&D spend for the coming year.

‘This is a remarkable achievement given the current financial climate and is the third consecutive year that we have achieved double digit figures in revenue growth’ said Dr Jas Sanghera, Commercial Director of TTP LabTech Ltd. ’I attribute the success to the company’s unique range of products, coupled with the first class customer service that I believe can only be provided by an employee-owned company such as ours.’ Importantly, TTP LabTech’s global presence has expanded over this period to include offices in the UK, US and China, with strong distributor representation in other key markets such as Europe and Asia-Pacific.

Considering the coming year, Dr Sanghera added ‘We have taken orders for a number of instruments in the first quarter of our financial year, and have put into place strategic initiatives that will hopefully allow us to keep this momentum in the current climate. To this end, we have also increased our R&D funding by 20% and we anticipate a new product launch for the drug discovery market within the next year. Furthermore, we intend to add a number of significant product enhancements to our existing portfolio, which demonstrates our continuing long-term commitment to providing superior products and support to our customers.’

About TTP LabTech Ltd

Based near Cambridge, UK, TTP LabTech Ltd (ttplabtech.com) is a leading provider of development services to the international life science community. TTP LabTech’s development teams combine skills in chemistry, biology, and engineering to provide systems, products, and processes which are both innovative and practical. With offices in the UK, North America, and China the company is able to manage and support custom development projects for client companies in virtually all parts of the world.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Alto Marketing Ltd

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


TTP LabTech Announces 25% Revenue Growth and A Push on R&D

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Leigh Dilley - Alto-Marketing.com 
+44(0)14 8955 7672 clarer[.]alto-marketing.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Alto Marketing Ltd securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Alto Marketing Ltd / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  RightITnow Ltd





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)